ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. T...
ZIM Laboratories reported revenue of 3.79 billion INR for fiscal year 2025, up 3.2% from fiscal year 2024, and net income of 121.65 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.09 billion INR, up 12.8% from a year before. Outside India was its largest region in fiscal year 2025, with 82% of revenue. Its market capitalization was 8.07 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.